» Articles » PMID: 10421262

A Controlled Study of Postoperative Radiotherapy for Patients with Completely Resected Nonsmall Cell Lung Carcinoma. Groupe D'Etude Et De Traitement Des Cancers Bronchiques

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1999 Jul 27
PMID 10421262
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postoperative radiotherapy is commonly used to treat patients with completely resected nonsmall cell lung carcinoma, but its effect on overall survival has not been established.

Methods: After undergoing complete surgical resection, 728 patients with non-small cell lung carcinoma (221 Stage I, 180 Stage II, and 327 Stage III) were randomized to receive either postoperative radiotherapy at a total dose of 60 gray or observation only . The main end point was overall survival.

Results: At the reference date, 218 of 355 patients in the control group had died and 262 of 373 in the radiotherapy group had died. Five-year overall survival was 43% for the control group and 30% for the radiotherapy group (P = 0.002, log rank test; relative risk [RR]: 1.33; 95% confidence interval [CI]: 1.11-1.59). This result was not modified by adjustment for potential prognostic factors. The excess mortality rate for the radiotherapy group was due to an excess of intercurrent deaths (P = 0.0001; RR: 3.47; the 5-year intercurrent death rate was 8% for the control group and 31% for the radiotherapy group). Radiotherapy had no significant effect on local recurrence (RR: 0.85; 95% CI: 0.64-1.14) and no effect on metastasis (RR: 1.06; 95% CI: 0.85-1.31). The rate of non-cancer-related death increased with the dose per fraction delivered.

Citing Articles

Postoperative radiotherapy improves survival in completely resected non-small cell lung cancer with pathologic N2 stage IIIA and positive lymph node count greater than one: a SEER-based retrospective cohort study.

Zhu D, Xiao Y, He S, Xie B, Zhao W, Xu Y Front Surg. 2025; 11:1506854.

PMID: 39968112 PMC: 11832526. DOI: 10.3389/fsurg.2024.1506854.


Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy.

Yilmaz M, Hurmuz P, Gurlek E, Yildiz D, Cengiz M Strahlenther Onkol. 2024; .

PMID: 39641790 DOI: 10.1007/s00066-024-02339-y.


Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer-A Review.

Suveg K, Plasswilm L, Iseli T, Leskow P, Fischer G, Putora P Cancers (Basel). 2022; 14(7).

PMID: 35406388 PMC: 8997169. DOI: 10.3390/cancers14071617.


A narrative review of postoperative adjuvant radiotherapy for non-small cell lung cancer.

Olmetto E, Perna M, Cerbai C, Aquilano M, Banini M, Mariotti M Mediastinum. 2022; 6:4.

PMID: 35340837 PMC: 8841548. DOI: 10.21037/med-21-31.


Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Sun X, Men Y, Wang J, Bao Y, Yang X, Zhao M Thorac Cancer. 2021; 12(9):1358-1365.

PMID: 33728811 PMC: 8088942. DOI: 10.1111/1759-7714.13908.